VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2021 | Total pain burden reduced by galcanezumab in treatment-resistant migraine

Jessica Ailani, MD, MedStar Georgetown University Hospital, Georgetown, Washington, DC, discusses an analysis of total pain burden in patients with treatment-resistant headache treated with galcanezumab in the Phase IIIb CONQUER trial (NCT03559257). The post-hoc analysis included 458 patients with chronic or episodic migraine and calculated total pain burden as a factor encompassing headache frequency, severity, and duration. A greater reduction in mean total pain burden was evident at month 1, 2 and 3 for those treated with galcanezumab compared to placebo. This improvement remained after adjustment for migraine frequency, suggesting an additional benefit to lowering duration and severity. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

Consulting: (Honoraria for independent consulting) Amgen, Abbvie, Biohaven, Eli Lilly and Company, Lundbeck, Teva, Impel, Satsuma, Theranica, Axsome, Neso, GlaxoSmithKline, Aeon, Medscape
Ownership of Stocks: CtrlM
Speakers Bureau: (Honoraria for promotional speaking) Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva
Editorial services: (Honoraria) Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, SELF (medical reviewer)
Clinical Trial Grants: (Fees to Institution) American Migraine Foundation, Allergan, Biohaven, Eli Lilly and Company, Satsuma, Zosano